Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH) (vol 5, pg 830, 2018)

被引：0
|
作者：
Pinto, Fausto [1 ]
机构：
[1] Univ Lisbon, Hosp Santa Maria, AIDFM, Cardiovasc Ctr,CHLN,CCUL,Dept Cardiol, Lisbon, Portugal
来源：
ESC HEART FAILURE | 2018年 / 5卷 / 06期
关键词：
D O I：
10.1002/ehf2.12374
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1199 / 1199
页数：1
相关论文
共 7 条
  • [1] Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH)
    Pouleur, Anne-Catherine
    Anker, Stefan
    Brito, Dulce
    Brosteanu, Oana
    Hasenclever, Dirk
    Casadei, Barbara
    Edelmann, Frank
    Filippatos, Gerasimos
    Gruson, Damien
    Ikonomidis, Ignatios
    Lhommel, Renaud
    Mahmod, Masliza
    Neubauer, Stefan
    Persu, Alexandre
    Gerber, Bernhard L.
    Piechnik, Stefan
    Pieske, Burkert
    Pieske-Kraigher, Elisabeth
    Pinto, Fausto
    Ponikowski, Piotr
    Senni, Michele
    Trochu, Jean-Noel
    Van Overstraeten, Nancy
    Wachter, Rolf
    Balligand, Jean-Luc
    ESC HEART FAILURE, 2018, 5 (05): : 831 - 842
  • [2] A Randomized, Multicenter, Placebo-Controlled Trial of the Beta3 Adrenergic Agonist, Mirabegron on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease, the Beta3lvh Trial
    Balligand, Jean-Luc
    CIRCULATION, 2022, 146 (25) : E591 - E591
  • [3] Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease The Beta3-LVH Phase 2b Randomized Clinical Trial
    Balligand, Jean-Luc
    Brito, Dulce
    Brosteanu, Oana
    Casadei, Barbara
    Depoix, Christophe
    Edelmann, Frank
    Ferreira, Vanessa
    Filippatos, Gerasimos
    Gerber, Bernhard
    Gruson, Damien
    Hasenclever, Dirk
    Hellenkamp, Kristian
    Ikonomidis, Ignatios
    Krakowiak, Bartosz
    Lhommel, Renaud
    Mahmod, Masliza
    Neubauer, Stefan
    Persu, Alexandre
    Piechnik, Stefan
    Pieske, Burkert
    Pieske-Kraigher, Elisabeth
    Pinto, Fausto
    Ponikowski, Piotr
    Senni, Michele
    Trochu, Jean-Noel
    Van Overstraeten, Nancy
    Wachter, Rolf
    Pouleur, Anne-Catherine
    JAMA CARDIOLOGY, 2023, 8 (11) : 1031 - 1040
  • [4] IMPROVEMENT OF LEFT-VENTRICULAR CONTRACTILITY AND RELAXATION WITH THE BETA-1-ADRENERGIC RECEPTOR PARTIAL AGONIST XAMOTEROL AT REST AND DURING EXERCISE IN PATIENTS WITH POSTINFARCTION LEFT-VENTRICULAR DYSFUNCTION - A PLACEBO-CONTROLLED RANDOMIZED TRIAL
    DEFEYTER, PJ
    SERRUYS, PW
    SURYAPRANATA, H
    CIRCULATION, 1990, 81 (02) : 99 - 106
  • [5] Chronic beta3-adrenergic receptor blockade limits the progression of heart failure:: Beneficial effects on left ventricular and myocyte function and [Ca2+]i regulation
    Morimoto, A
    Han, QH
    Cheng, HJ
    Hasegawa, H
    Cheng, CP
    CIRCULATION, 2003, 108 (17) : 413 - 414
  • [6] Intravenous Infusion of the beta-3 Adrenergic Receptor Antagonist APD418 Improves Left Ventricular Systolic and Diastolic Function in Dogs with Heart Failure: A Single Dose, 6 Hours Study
    Sabbah, Hani N.
    Zhang, Kefei
    Xu, Jiang
    Gupta, Ramesh C.
    Adams, John
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S8 - S8
  • [7] Protocol for a multicenter randomized, double blind, controlled pilot trial of higher neural function in overactive bladder patients after anticholinergic, beta-3 adrenergic agonist, or placebo (vol 19, 100621, 2020)
    High, R. A.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 20
1